Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 5, Number 5, October 2013, pages 401-406

Participant Preferences for the Provision of Registration Trials Results

Tables

Table 1. Preference for Receiving Information on Allocation in a Registration Trial
 
Strongly agreeAgreeNeutralDisagreeStrongly disagreeNo answerTotal
a. Do you want to be informed concerning your own allocation in the registration trial?/td>29 (50.9%)14 (24.6%)1 (1.8%)3 (5.3%)010 (17.5%)57
b. Do you want to be informed concerning your own allocation in the registration trial, even if you were treated with placebo?/td>28 (49.1%)14 (24.6%)2 (3.5%)2 (3.5%)1 (1.8%)10 (17.5%)57

 

Table 2. Preference for Receiving Information on the Results of Registration Trials
 
Strongly agreeAgreeNeutralDisagreeStrongly disagreeNo answerTotal
a. Do you want to be informed of the results (efficacy and safety) of the registration trial in which you participated?/td>34 (59.6%)17 (29.8%)2 (3.5%)1 (1.8%)1 (1.8%)2 (3.5%)57
b. Do you want to be informed of the results (efficacy and safety) of the registration trial in which you participated, even if negative?/td>31 (49.1%)17 (29.8%)4 (7.0%)1 (1.8%)1 (1.8%)3 (5.3%)57
c. Do you want to be informed of the state of labeling of the drug examined in the registration trial in which you participated?/td>32 (56.1%)13 (22.8%)5 (8.8%)007 (12.3%)57
d. Do you want to be informed of the state of labeling of the drug examined in the registration trial in which you participated, even if drug development has ceased?/td>30 (52.6%)15 (26.3%)7 (12.3%)1 (1.8%)04 (7.0%)57

 

Table 3. Preferences for Receiving Information on Allocation in the Trial and on the State of Registration Trials, Depending on the Type of Disease
 
Participants who agreed to provision of information
Participants with difficult-to-treat diseases (n = 36)Participants with other types of diseases (n = 21)
a, b, c, d, e, fSignificant differences (P = 0.008, 0.005, 0.048, 0.013, 0.021, 0.021, respectively) compared with participants with difficult-to-treat diseases.
1-a. Do you want to be informed of your allocation in the registration trial?/td>23 (63.9%)20 (95.2%) a
1-b. Do you want to be informed of your own allocation in the registration trial, even if you were treated with placebo?/td>22 (61.1%)20 (95.2%) b
2-a. Do you want to be informed of the result (efficacy and safety) of the registration trial in which you participated?/td>30 (83.3%)21 (100%) c
2-b. Do you want to be informed of the result (efficacy and safety) of the registration trial that you participated, even if negative?/td>27 (75.0%)21 (100%) d
2-c. Do you want to be informed of the state of labeling of the drug examined in the registration trial in which you participated?/td>25 (69.4%)20 (95.2%) e
2-d. Do you want to be informed of the state of labeling of the drug examined in the registration trial in which you participated, even if drug development has ceased?/td>25 (69.4%)20 (95.2%) f

 

Table 4. Preferences Means of Receiving Information on the Results of Registration Trials
 
PhysicianCRCOfficerNo answerTotal
E-mail1 (1.8%)0001 (1.8%)
Telephone1 (1.8%)1 (1.8%)002 (3.5%)
Posted letter8 (14.0%)7 (12.3%)4 (7.0%)019 (33.3%)
Face-to-face25 (43.9%)6 (10.5%)1 (1.8%)032 (56.1%)
No answer0003 (5.3%)3 (5.3%)
Total35 (61.4%)14 (24.6%)5 (8.8%)3 (5.3%)57 (100%)